Combined Haploidentical-Cord Blood Transplantation for Adults and Children

• Status: Completed
• Trial end date: 2018-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease (GVHD).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Antilymphocyte Serum; Busulfan; Fludarabine; Fludarabine phosphate; Melphalan; Thiotepa; Thymoglobulin; Vidarabine

Criteria

Inclusion Criteria:

Patients will be eligible for this study if they have any one of the diseases that are known to be cured after allogeneic stem cell transplantation.

1. Relapsed or refractory acute leukemia (myeloid or lymphoid)

2. Acute leukemia in first remission at high-risk for recurrence

3. Chronic myelogenous leukemia in accelerated phase or blast-crisis

4. Chronic myelogenous leukemia in chronic phase

5. Recurrent or refractory malignant lymphoma or Hodgkin lymphoma

6. Chronic lymphocytic leukemia, relapsed or with poor prognostic features

7. Multiple myeloma

8. Myelodysplastic syndrome

9. Chronic myeloproliferative disease

10. Hemoglobinopathies

11. Aplastic anemia

Exclusion Criteria:

1. Zubrod performance status > 2

2. Life expectancy is severely limited by concomitant illness

3. Patients with severely decreased LVEF or impaired pulmonary function tests(PFT's)

4. Estimated Creatinine Clearance <50 ml/min

5. Serum bilirubin> 2.0 mg/dl or SGPT >3 x upper limit of normal

6. Evidence of chronic active hepatitis or cirrhosis

7. HIV-positive

8. Patient is pregnant

9. Patient or guardian not able to sign informed consent